FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Olavi Pelkonen

Research Profile

Chemicals & Drugs

Anatomy

Living Beings

Physiology

Activities & Behaviors

Smoking

Phenomena

Hydroxylation

Co-author Network

Publications

TOP 3
Olavi Pelkonen; Hannu Raunio; Miia Turpeinen; khaled Abass; Jukka Hakkola; Markku Pasanen; Kirsi Vähäkangas
Preservation, induction or incorporation of metabolism into the in vitro cellular system - Views to current opportunities and limitations.
khaled Abass; Olavi Pelkonen
The inhibition of major human hepatic cytochrome P450 enzymes by 18 pesticides: Comparison of the N-in-one and single substrate approaches.
Olavi Pelkonen; Khaled Abass; Jacqueline Wiesner
Thujone and thujone-containing herbal medicinal and botanical products: toxicological assessment.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Olavi Pelkonen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Olavi Pelkonen; Hannu Raunio; Miia Turpeinen; khaled Abass; Jukka Hakkola; Markku Pasanen; Kirsi Vähäkangas
Preservation, induction or incorporation of metabolism into the in vitro cellular system - Views to current opportunities and limitations.
Toxicology in vitro : an international journal published in association with BIBRA 2013;27(5):1578-83.
2013: khaled Abass; Olavi Pelkonen
The inhibition of major human hepatic cytochrome P450 enzymes by 18 pesticides: Comparison of the N-in-one and single substrate approaches.
Toxicology in vitro : an international journal published in association with BIBRA 2013;27(5):1584-8.
2013: Olavi Pelkonen; Khaled Abass; Jacqueline Wiesner
Thujone and thujone-containing herbal medicinal and botanical products: toxicological assessment.
Regulatory toxicology and pharmacology : RTP 2013;65(1):100-7.
2012: Olavi Pelkonen; Qihe Xu; Liping Zhao; Kelvin Chan; Greer Deal; John C Lindon; Markku Pasanen; Tai-Ping Fan
Omics and its potential impact on R&D and regulation of complex herbal products.
Journal of ethnopharmacology 2012;140(3):587-93.
2012: khaled Abass; Paavo Honkakoski; Jenni Küblbeck; Virpi Lämsä; Sampo Mattila; Olavi Pelkonen; Petri Reponen; Jukka Hakkola
Characterization of human cytochrome P450 induction by pesticides.
Toxicology 2012;294(1):17-26.
2012: Mari Murtomaa-Hautala; Olavi Pelkonen; Raimo Pohjanvirta; Arja Rautio; Pirkko Viitala; Nagabhooshan Hegde; Heikki Henttonen; Otso Huitu; Merja Korkalainen; Matti Viluksela
Significant interspecies differences in induction profiles of hepatic CYP enzymes by TCDD in bank and field voles.
Environmental toxicology and chemistry / SETAC 2012;31(3):663-71.
2011: Olavi Pelkonen; Miia Turpeinen; Hannu Raunio
In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions.
Clinical pharmacokinetics 2011;50(8):483-91.
2011: Marjo Volotinen; Jukka Hakkola; Olavi Pelkonen; Heikki Vapaatalo; Jukka Mäenpää
Metabolism of ophthalmic timolol: new aspects of an old drug.
Basic & clinical pharmacology & toxicology 2011;108(5):297-303.
2011: Khaled Abass; Petri Reponen; Sampo Mattila; Olavi Pelkonen
Metabolism of α-thujone in human hepatic preparations in vitro.
Xenobiotica; the fate of foreign compounds in biological systems 2011;41(2):101-11.
2010: Khaled Abass; Petri Reponen; Sampo Mattila; Olavi Pelkonen
Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved.
Chemico-biological interactions 2010;185(3):163-73.
2010: Marjo Volotinen; Timo Korjamo; Ari Tolonen; Miia Turpeinen; Olavi Pelkonen; Jukka Hakkola; Jukka Mäenpää
Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes.
Basic & clinical pharmacology & toxicology 2010;106(4):302-9.
2010: Mari Murtomaa; Olavi Pelkonen; Juho Hokkanen; Pirkko Viitala; Arja Rautio
Xenobiotic metabolism of bank vole (Myodes glareolus) exposed to PCDDs.
Environmental toxicology and pharmacology 2010;29(1):19-23.
2010: Olavi Pelkonen
Predictive toxicity: grand challenges.
Frontiers in pharmacology 2010;1():3.
2009: Khaled Abass; Petri Reponen; Sampo Mattila; Olavi Pelkonen
Metabolism of carbosulfan. I. Species differences in the in vitro biotransformation by mammalian hepatic microsomes including human.
Chemico-biological interactions 2009;181(2):210-9.
2009: Khaled Abass; Miia Turpeinen; Olavi Pelkonen
An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes.
Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes 2009;44(6):553-63.
2009: Marjo Volotinen; Jukka Mäenpää; Esko Kankuri; Olli Oksala; Olavi Pelkonen; Miki Nakajima; Tsuyoshi Yokoi; Jukka Hakkola
Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD.
Investigative ophthalmology & visual science 2009;50(7):3099-105.
2009: Miia Turpeinen; Ari Tolonen; Christophe Chesne; André Guillouzo; Jouko Uusitalo; Olavi Pelkonen
Functional expression, inhibition and induction of CYP enzymes in HepaRG cells.
Toxicology in vitro : an international journal published in association with BIBRA 2009;23(4):748-53.
2009: Olavi Pelkonen; Ari Tolonen; Timo Korjamo; Miia Turpeinen; Hannu Raunio
From known knowns to known unknowns: predicting in vivo drug metabolites.
Bioanalysis 2009;1(2):393-414.
2009: Olavi Pelkonen
[Why does acetylsalicylic acid have so many effects and applications?].
Duodecim; lääketieteellinen aikakauskirja 2009;125(22):2433-9.
2009: Olavi Pelkonen; Ari Tolonen; Timo Rousu; Larissa Tursas; Miia Turpeinen; Juho Hokkanen; Jouko Uusitalo; Michael Bouvier d'Yvoire; Sandra Coecke
Comparison of metabolic stability and metabolite identification of 55 ECVAM/ICCVAM validation compounds between human and rat liver homogenates and microsomes - a preliminary analysis.
ALTEX 2009;26(3):214-22.
2008: Aleksanteri Petsalo; Miia Turpeinen; Olavi Pelkonen; Ari Tolonen
Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 microm particle size column.
Journal of chromatography. A 2008;1215(1-2):107-15.
2008: Olavi Pelkonen; Miia Turpeinen; Jukka Hakkola; Paavo Honkakoski; Janne Hukkanen; Hannu Raunio
Inhibition and induction of human cytochrome P450 enzymes: current status.
Archives of toxicology 2008;82(10):667-715.
2008: Satu Arpiainen; Sanna-Mari Järvenpää; Aki Manninen; Pirkko Viitala; Matti A Lang; Olavi Pelkonen; Jukka Hakkola
Coactivator PGC-1alpha regulates the fasting inducible xenobiotic-metabolizing enzyme CYP2A5 in mouse primary hepatocytes.
Toxicology and applied pharmacology 2008;232(1):135-41.
2008: Minna Rahnasto; Carsten Wittekindt; Risto O Juvonen; Miia Turpeinen; A Petsalo; Olavi Pelkonen; Antti Poso; Gunther Stahl; H-D Höltje; Hannu Raunio
Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach.
The pharmacogenomics journal 2008;8(5):328-38.
2008: Olavi Pelkonen; Jukka Hakkola
Cytochromes P450, induction and cholesterol--what are the connections?
European journal of clinical pharmacology 2008;64(9):837-9.
2008: Tuomas Korhonen; Miia Turpeinen; Ari Tolonen; Kari Laine; Olavi Pelkonen
Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone.
The Journal of steroid biochemistry and molecular biology 2008;110(1-2):56-66.
2008: Hannu Koponen; Antti Alaräisänen; Kaisa Saari; Olavi Pelkonen; Heikki Huikuri; M J Pekka Raatikainen; Markku Savolainen; Matti Isohanni
Schizophrenia and sudden cardiac death: a review.
Nordic journal of psychiatry 2008;62(5):342-5.
2008: Olavi Pelkonen; Jaime Kapitulnik; Ursula Gundert-Remy; Alan R Boobis; Armel Stockis
Local kinetics and dynamics of xenobiotics.
Critical reviews in toxicology 2008;38(8):697-720.
2007: M Turpeinen; C Ghiciuc; M Opritoui; L Tursas; Olavi Pelkonen; M Pasanen
Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro.
Xenobiotica; the fate of foreign compounds in biological systems 2007;37(12):1367-77.
2007: Olavi Pelkonen; M Turpeinen
In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations.
Xenobiotica; the fate of foreign compounds in biological systems 2007;37(10-11):1066-89.
2007: khaled Abass; Petri Reponen; Miia Turpeinen; Jorma Jalonen; Olavi Pelkonen
Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(9):1634-41.
2007: Miia Turpeinen; Niina Koivuviita; Ari Tolonen; Petri Reponen; Stefan Lundgren; Jouko Miettunen; Kaj Metsärinne; Anders Rane; Olavi Pelkonen; Kari Laine
Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites.
British journal of clinical pharmacology 2007;64(2):165-73.
2007: Ari Tolonen; Aleksanteri Petsalo; Miia Turpeinen; Jouko Uusitalo; Olavi Pelkonen
In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies.
Journal of mass spectrometry : JMS 2007;42(7):960-6.
2007: Marjo Volotinen; Miia Turpeinen; Ari Tolonen; Jouko Uusitalo; Jukka Mäenpää; Olavi Pelkonen
Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(7):1135-41.
2007: Satu Arpiainen; Virpi Lämsä; Olavi Pelkonen; Sun Hee Yim; Frank J Gonzalez; Jukka Hakkola
Aryl hydrocarbon receptor nuclear translocator and upstream stimulatory factor regulate Cytochrome P450 2a5 transcription through a common E-box site.
Journal of molecular biology 2007;369(3):640-52.
2007: Olavi Pelkonen
Metabolism and pharmacokinetics in children and the elderly.
Expert opinion on drug metabolism & toxicology 2007;3(2):147-8.
2007: Laura E Korhonen; Miia Turpeinen; Minna Rahnasto; Carsten Wittekindt; Antti Poso; Olavi Pelkonen; Hannu Raunio; Risto O Juvonen
New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis.
British journal of pharmacology 2007;150(7):932-42.
2007: Eivor Elovaara; Jouni Mikkola; Helene Stockmann-Juvala; Leena Luukkanen; Helena Keski-Hynnilä; Risto Kostiainen; Markku Pasanen; Olavi Pelkonen; Harri Vainio
Polycyclic aromatic hydrocarbon (PAH) metabolizing enzyme activities in human lung, and their inducibility by exposure to naphthalene, phenanthrene, pyrene, chrysene, and benzo(a)pyrene as shown in the rat lung and liver.
Archives of toxicology 2007;81(3):169-82.
2007: khaled Abass; Jorma Jalonen; Petri Reponen; Olavi Pelkonen
In vitro metabolism and interactions of the fungicide metalaxyl in human liver preparations.
Environmental toxicology and pharmacology 2007;23(1):39-47.
2007: Lorenz R Rhomberg; Karl Baetcke; Jerry Blancato; James Bus; Samuel Cohen; Rory B Conolly; Rakesh Dixit; John Doe; Karen Ekelman; Penelope A Fenner-Crisp; Paul Harvey; Dale Hattis; Abigail Jacobs; David Jacobson-Kram; Tom Lewandowski; Robert Liteplo; Olavi Pelkonen; Jerry Rice; Diana Somers; Angelo Turturro; Webster West; Stephen Olin
Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.
Critical reviews in toxicology 2007;37(9):729-837.
2007: Zoe E Barter; Martin K Bayliss; Philip H Beaune; Alan R Boobis; David J Carlile; Robert J Edwards; J Brian Houston; Brian G Lake; John C Lipscomb; Olavi Pelkonen; Geoffrey T Tucker; Amin Rostami-Hodjegan
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Current drug metabolism 2007;8(1):33-45.
2006: Hannu-Ville Leskelä; Anu Olkku; Siri Lehtonen; Anitta Mahonen; Jussi Koivunen; Miia Turpeinen; Jouko Uusitalo; Olavi Pelkonen; Lauri Kangas; Katri Selander; Petri Lehenkari
Estrogen receptor alpha genotype confers interindividual variability of response to estrogen and testosterone in mesenchymal-stem-cell-derived osteoblasts.
Bone 2006;39(5):1026-34.
2006: Miia Turpeinen; Hannu Raunio; Olavi Pelkonen
The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico.
Current drug metabolism 2006;7(7):705-14.
2006: Miia Turpeinen; Laura E Korhonen; Ari Tolonen; Jouko Uusitalo; Risto O Juvonen; Hannu Raunio; Olavi Pelkonen
Cytochrome P450 (CYP) inhibition screening: comparison of three tests.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2006;29(2):130-8.
2006: Timo Korjamo; Jukka Mönkkönen; Jouko Uusitalo; Miia Turpeinen; Olavi Pelkonen; Paavo Honkakoski
Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors.
Pharmaceutical research 2006;23(9):1991-2001.
2006: Rolf Schulte-Hermann; Gerald N Wogan; Colin Berry; Nigel A Brown; Andrew E Czeizel; Erminio Giavini; Lewis B Holmes; Robert Kroes; Heinz Nau; Diether Neubert; Franz Oesch; Tilmann Ott; Olavi Pelkonen; Elisabeth Robert-Gnansia; Frank M Sullivan
Analysis of reproductive toxicity and classification of glufosinate-ammonium.
Regulatory toxicology and pharmacology : RTP 2006;44(3 Suppl 1):S1-76.
2005: Susanne Bremer; Rita Cortvrindt; George P Daston; Brighitta Eletti; Alberto Mantovani; Francesca Maranghi; Olavi Pelkonen; Irmela Ruhdel; Horst Spielmann
Reproductive and developmental toxicity.
Alternatives to laboratory animals : ATLA 2005;33 Suppl 1():183-209.
2005: Sandra Coecke; Bas J Blaauboer; Greetje Elaut; Stuart Freeman; Andreas P Freidig; Nigel Gensmantel; Peter Hoet; Vassilios M Kapoulas; Bernhard Ladstetter; Gill Langley; David Leahy; Geert Mannens; Annarita Meneguz; Mario Monshouwer; Ben Nemery; Olavi Pelkonen; Walter Pfaller; Pilar Prieto; Nick Proctor; Vera Rogiers; Amin Rostami-Hodjegan; Enrico Sabbioni; Winfried Steiling; Johannes J M van de Sandt
Toxicokinetics and metabolism.
Alternatives to laboratory animals : ATLA 2005;33 Suppl 1():147-75.
2005: Olavi Pelkonen; Hannu Raunio
In vitro screening of drug metabolism during drug development: can we trust the predictions?
Expert opinion on drug metabolism & toxicology 2005;1(1):49-59.
2005: Miia Turpeinen; Ari Tolonen; Jouko Uusitalo; Jorma Jalonen; Olavi Pelkonen; Kari Laine
Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
Clinical pharmacology and therapeutics 2005;77(6):553-9.
2005: Ari Tolonen; Miia Turpeinen; Jouko Uusitalo; Olavi Pelkonen
A simple method for differentiation of monoisotopic drug metabolites with hydrogen-deuterium exchange liquid chromatography/electrospray mass spectrometry.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2005;25(1):155-62.
2005: Paivi Myllynen; Markku Pasanen; Olavi Pelkonen
Human placenta: a human organ for developmental toxicology research and biomonitoring.
Placenta 2005;26(5):361-71.
2005: Ursula Gundert-Remy; Svein G Dahl; Alan R Boobis; Pierre Kremers; Annette Kopp-Schneider; Axel Oberemm; Andrew Renwick; Olavi Pelkonen
Molecular approaches to the identification of biomarkers of exposure and effect--report of an expert meeting organized by COST Action B15. November 28, 2003.
Toxicology letters 2005;156(2):227-40.
2005: Satu Arpiainen; Françoise Raffalli-Mathieu; Matti A Lang; Olavi Pelkonen; Jukka Hakkola
Regulation of the Cyp2a5 gene involves an aryl hydrocarbon receptor-dependent pathway.
Molecular pharmacology 2005;67(4):1325-33.
2005: Olavi Pelkonen; Miia Turpeinen; Jouko Uusitalo; Arja Rautio; Hannu Raunio
Prediction of drug metabolism and interactions on the basis of in vitro investigations.
Basic & clinical pharmacology & toxicology 2005;96(3):167-75.
2005: Hannu Raunio; Jukka Hakkola; Olavi Pelkonen
Regulation of CYP3A genes in the human respiratory tract.
Chemico-biological interactions 2005;151(2):53-62.
2005: Markku Anttila; Eero A Sotaniemi; Olavi Pelkonen; Arja Rautio
Marked effect of liver and kidney function on the pharmacokinetics of selegiline.
Clinical pharmacology and therapeutics 2005;77(1):54-62.
2005: Miia Turpeinen; Jouko Uusitalo; Uusitalo Jouko; Jorma Jalonen; Jalonen Jorma; Olavi Pelkonen; Pelkeonen Olavi
Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2005;24(1):123-32.
2004: Hannu Raunio; Päivi Taavitsainen; Paavo Honkakoski; Risto O Juvonen; Olavi Pelkonen
In vitro methods in the prediction of kinetics of drugs: focus on drug metabolism.
Alternatives to laboratory animals : ATLA 2004;32(4):425-30.
2004: Johanna Ulvila; Satu Arpiainen; Olavi Pelkonen; Kaoru Aida; Tatsuya Sueyoshi; Masahiko Negishi; Jukka Hakkola
Regulation of Cyp2a5 transcription in mouse primary hepatocytes: roles of hepatocyte nuclear factor 4 and nuclear factor I.
The Biochemical journal 2004;381(Pt 3):887-94.
2004: Miia Turpeinen; Riina Nieminen; Tarja Juntunen; Päivi Taavitsainen; Hannu Raunio; Olavi Pelkonen
Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(6):626-31.
2003: Nilgun Kapucuoglu; Tülay Coban; Hannu Raunio; Olavi Pelkonen; Robert J Edwards; Alan R Boobis; Mümtaz Iscan
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Cancer letters 2003;202(1):17-23.
2003: Janne Mäkinen; Mika Reinisalo; Kaisa Niemi; Pirkko Viitala; Johanna Jyrkkärinne; Hinfan Chung; Olavi Pelkonen; Paavo Honkakoski
Dual action of oestrogens on the mouse constitutive androstane receptor.
The Biochemical journal 2003;376(Pt 2):465-72.
2003: Sanna Palovaara; Olavi Pelkonen; Jouko Uusitalo; Stefan Lundgren; Kari Laine
Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation.
Clinical pharmacology and therapeutics 2003;74(4):326-33.
2003: Jarmo S Salonen; Leena Nyman; Alan R Boobis; Robert J Edwards; Patricia Watts; Brian G Lake; Roger J Price; Anthony B Renwick; M José Gómez-Lechón; José V Castell; Magnus Ingelman-Sundberg; Mats Hidestrand; André Guillouzo; Laurent Corcos; Peter S Goldfarb; David F V Lewis; Päivi Taavitsainen; Olavi Pelkonen
Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(9):1093-102.
2003: Nilgun Kapucuoglu; Tülay Coban; Hannu Raunio; Olavi Pelkonen; Robert J Edwards; Alan R Boobis; Mümtaz Iscan
Immunohistochemical demonstration of the expression of CYP2E1 in human breast tumour and non-tumour tissues.
Cancer letters 2003;196(2):153-9.
2003: Annaliisa Jäppinen; Miia Turpeinen; Hannu Kokki; Anu Rasi; Tarja Ojanen; Olavi Pelkonen; Toivo Naaranlahti
Stability of sufentanil and levobupivacaine solutions and a mixture in a 0.9% sodium chloride infusion stored in polypropylene syringes.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2003;19(1):31-6.
2003: Janne Hukkanen; Teemu Väisänen; Arja Lassila; Ritva Piipari; Sisko Anttila; Olavi Pelkonen; Hannu Raunio; Jukka Hakkola
Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells.
The Journal of pharmacology and experimental therapeutics 2003;304(2):745-52.
2003: Madeleine Nyman; Magnus Bergknut; Marie Louise Fant; Hannu Raunio; Marika Jestoi; Charlotta Bengs; Albertinka J Murk; Jaana Koistinen; Christina Bäckman; Olavi Pelkonen; Mats Tysklind; Timo Hirvi; Eero Helle
Contaminant exposure and effects in Baltic ringed and grey seals as assessed by biomarkers.
Marine environmental research 2003;55(1):73-99.
2003: Tuija Liukkonen-Anttila; Henrika Honkanen; Päivi Peltokangas; Olavi Pelkonen; Esa Hohtola
Cytochrome P450 enzyme activity in five herbivorous, non-passerine bird species.
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 2003;134(1):69-77.
2002: Alan R Boobis; Ursula Gundert-Remy; Pierre Kremers; Panos Macheras; Olavi Pelkonen
In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2002;17(4-5):183-93.
2002: Janne Hukkanen; Olavi Pelkonen; Jukka Hakkola; Hannu Raunio
Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung.
Critical reviews in toxicology 2002;32(5):391-411.
2002: Eero A Sotaniemi; Olavi Pelkonen; Arno J Arranto; Päivi Tapanainen; Arja Rautio; Markku Pasanen
Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement.
Pharmacology & toxicology 2002;90(3):155-60.
2002: Olavi Pelkonen
Human CYPs: in vivo and clinical aspects.
Drug metabolism reviews 2002;34(1-2):37-46.
2002: Sami Tetri; Minna Ruhanen; Pirkko Viitala; Olavi Pelkonen; Markku Pasanen; Hannu Raunio
Lack of association between CYP2A5 induction and apoptosis in mouse primary hepatocytes.
Biochemical pharmacology 2002;63(3):429-35.
2002: Olavi Pelkonen; Janne Hukkanen; Paavo Honkakoski; Jukka Hakkola; Pirkko Viitala; Hannu Raunio
In vitro screening of cytochrome P450 induction potential.
Ernst Schering Research Foundation workshop 2002;(37):105-37.
2001: Olavi Pelkonen; Alan R Boobis; U Gundert-Remy
In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report.
European journal of clinical pharmacology 2001;57(9):621-9.
2001: Mümtaz Iscan; T Klaavuniemi; Tülay Coban; Nilgun Kapucuoglu; Olavi Pelkonen; Hannu Raunio
The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue.
Breast cancer research and treatment 2001;70(1):47-54.
2001: Mats Hidestrand; Mikael Oscarson; Jarmo S Salonen; Leena Nyman; Olavi Pelkonen; M Turpeinen; Magnus Ingelman-Sundberg
CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(11):1480-4.
2001: Hannu Raunio; Arja Rautio; H Gullstén; Olavi Pelkonen
Polymorphisms of CYP2A6 and its practical consequences.
British journal of clinical pharmacology 2001;52(4):357-63.
2001: Benoit Nemery; A Bast; Jürgen Behr; Paul J A Borm; S J Bourke; Philippe Camus; P De Vuyst; H M Jansen; V L Kinnula; D Lison; Olavi Pelkonen; C Saltini
Interstitial lung disease induced by exogenous agents: factors governing susceptibility.
The European respiratory journal. Supplement 2001;32():30s-42s.
2001: Janne Hukkanen; Olavi Pelkonen; Hannu Raunio
Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: possible role in susceptibility for ILD.
The European respiratory journal. Supplement 2001;32():122s-126s.
2001: Olavi Pelkonen; Paivi Myllynen; Päivi Taavitsainen; Alan R Boobis; P Watts; Brian G Lake; Roger J Price; Anthony B Renwick; M José Gómez-Lechón; J V Castell; Magnus Ingelman-Sundberg; Mats Hidestrand; André Guillouzo; Laurent Corcos; Peter S Goldfarb; David F V Lewis
Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems.
Xenobiotica; the fate of foreign compounds in biological systems 2001;31(6):321-43.
2001: O M Hyyti; M Nyman; M L Willis; Hannu Raunio; Olavi Pelkonen
Distribution of cytochrome P4501A (CYP1A) in the tissues of Baltic ringed and grey seals.
Marine environmental research 2001;51(5):465-85.
2001: Tommy B Andersson; H Sjöberg; K J Hoffmann; Alan R Boobis; P Watts; R J Edwards; Brian G Lake; Roger J Price; Anthony B Renwick; M José Gómez-Lechón; J V Castell; Magnus Ingelman-Sundberg; Mats Hidestrand; Peter S Goldfarb; David F V Lewis; Laurent Corcos; André Guillouzo; Päivi Taavitsainen; Olavi Pelkonen
An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(5):712-20.
2001: Päivi Taavitsainen; Risto O Juvonen; Olavi Pelkonen
In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(3):217-22.
2001: Pirkko Viitala; K Posti; Aija Lindfors; Olavi Pelkonen; Hannu Raunio
cAMP mediated upregulation of CYP2A5 in mouse hepatocytes.
Biochemical and biophysical research communications 2001;280(3):761-7.
2001: Olavi Pelkonen
[Drugs and the masculinity].
Duodecim; lääketieteellinen aikakauskirja 2001;117(19):1980-6.
2001: Jukka Hakkola; Hannu Raunio; R Purkunen; S Saarikoski; Kirsi Vähäkangas; Olavi Pelkonen; R J Edwards; Alan R Boobis; Markku Pasanen
Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers.
Biology of the neonate 2001;80(3):193-201.
2001: Madeleine Nyman; Hannu Raunio; Päivi Taavitsainen; Olavi Pelkonen
Characterization of xenobiotic-metabolizing cytochrome P450 (CYP) forms in ringed and grey seals from the Baltic Sea and reference sites.
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 2001;128(1):99-112.
2000: M Teresa Donato; Pirkko Viitala; C Rodriguez-Antona; Aija Lindfors; José V Castell; Hannu Raunio; M José Gómez-Lechón; Olavi Pelkonen
CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(11):1321-6.
2000: Anthony B Renwick; Patricia S Watts; Robert J Edwards; PT Barton; I Guyonnet; Roger J Price; J Michael Tredger; Olavi Pelkonen; Alan R Boobis; Brian G Lake
Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(10):1202-9.
2000: A Karjalainen; A Kalapudas; M Södervall; Olavi Pelkonen; R Lammintausta
Synthesis of new potent and selective aromatase inhibitors based on long-chained diarylalkylimidazole and diarylalkyltriazole molecule skeletons.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2000;11(2):109-31.
2000: Päivi Taavitsainen; K Kiukaanniemi; Olavi Pelkonen
In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
European journal of clinical pharmacology 2000;56(2):135-40.
2000: Päivi Taavitsainen; Markku Anttila; Leena Nyman; H Karnani; Jarmo S Salonen; Olavi Pelkonen
Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Pharmacology & toxicology 2000;86(5):215-21.
2000: Olavi Pelkonen; Arja Rautio; Hannu Raunio; Markku Pasanen
CYP2A6: a human coumarin 7-hydroxylase.
Toxicology 2000;144(1-3):139-47.
2000: P Paakki; Pertti Kirkinen; H Helin; Olavi Pelkonen; Hannu Raunio; Markku Pasanen
Antepartum glucocorticoid therapy suppresses human placental xenobiotic and steroid metabolizing enzymes.
Placenta 2000;21(2-3):241-6.
2000: Janne Hukkanen; Arja Lassila; K Päivärinta; S Valanne; S Sarpo; Jukka Hakkola; Olavi Pelkonen; Hannu Raunio
Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line.
American journal of respiratory cell and molecular biology 2000;22(3):360-6.
2000: Olavi Pelkonen
[On the body's defense mechanisms against poisons].
Duodecim; lääketieteellinen aikakauskirja 2000;116(15):1610-3.
1999: A Brittelli; C De Santi; H Raunio; Olavi Pelkonen; G Rossi; Gian Maria Pacifici
Interethnic and interindividual variabilities of platelet sulfotransferases activity in Italians and Finns.
European journal of clinical pharmacology 1999;55(9):691-5.
1999: Mikael Oscarson; Roman A McLellan; H Gullstén; José Agúndez; Julio Benitez; Arja Rautio; Hannu Raunio; Olavi Pelkonen; Magnus Ingelman-Sundberg
Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.
FEBS letters 1999;460(2):321-7.
1999: K Posti; Sanna Leinonen; S Tetri; S Kottari; Pirkko Viitala; Olavi Pelkonen; Hannu Raunio
Modulation of murine phenobarbital-inducible CYP2A5, CYP2B10 and CYP1A enzymes by inhibitors of protein kinases and phosphatases.
European journal of biochemistry / FEBS 1999;264(1):19-26.
1999: Hannu Raunio; Jukka Hakkola; Janne Hukkanen; Arja Lassila; K Päivärinta; Olavi Pelkonen; Sisko Anttila; Ritva Piipari; Alan R Boobis; R J Edwards
Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue.
Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie 1999;51(4-5):412-7.
1999: Sanna Koskela; Jukka Hakkola; Janne Hukkanen; Olavi Pelkonen; Martti Sorri; A Saranen; Sisko Anttila; Pedro Fernandez-Salguero; F Gonzalez; Hannu Raunio
Expression of CYP2A genes in human liver and extrahepatic tissues.
Biochemical pharmacology 1999;57(12):1407-13.
1999: Mikael Oscarson; Roman A McLellan; H Gullstén; Q Y Yue; M A Lang; M L Bernal; Blanca Sinues; A Hirvonen; Hannu Raunio; Olavi Pelkonen; Magnus Ingelman-Sundberg
Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population.
FEBS letters 1999;448(1):105-10.
1999: Hannu Raunio; Arja Rautio; Olavi Pelkonen
The CYP2A subfamily: function, expression and genetic polymorphism.
IARC scientific publications 1999;(148):197-207.
1999: Olavi Pelkonen; Hannu Raunio; Arja Rautio; M Lang
Xenobiotic-metabolizing enzymes and cancer risk: correspondence between genotype and phenotype.
IARC scientific publications 1999;(148):77-88.
1999: M Lang; Olavi Pelkonen
Metabolism of xenobiotics and chemical carcinogenesis.
IARC scientific publications 1999;(148):13-22.
1998: Olavi Pelkonen; Jukka Mäenpää; Päivi Taavitsainen; Arja Rautio; Hannu Raunio
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
Xenobiotica; the fate of foreign compounds in biological systems 1998;28(12):1203-53.
1998: Mikael Oscarson; H Gullstén; Arja Rautio; M L Bernal; Blanca Sinues; Marja-Liisa Dahl; J H Stengård; Olavi Pelkonen; Hannu Raunio; Magnus Ingelman-Sundberg
Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase.
FEBS letters 1998;438(3):201-5.
1998: VS Haritos; Michael S Ching; Hany Ghabrial; Annette Gross; P Taavitsainen; Olavi Pelkonen; S E Battaglia; Richard A Smallwood; Jorma Ahokas
Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2.
Pharmacogenetics 1998;8(5):423-32.
1998: H Scheinin; Markku Anttila; M L Dahl; H Karnani; Leena Nyman; Päivi Taavitsainen; Olavi Pelkonen; Leif Bertilsson
CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Clinical pharmacology and therapeutics 1998;64(4):402-11.
1998: A Kojo; Pirkko Viitala; Markku Pasanen; Olavi Pelkonen; Hannu Raunio; Risto O Juvonen
Induction of CYP2A5 by pyrazole and its derivatives in mouse primary hepatocytes.
Archives of toxicology 1998;72(6):336-41.
1998: Jukka Hakkola; E Tanaka; Olavi Pelkonen
Developmental expression of cytochrome P450 enzymes in human liver.
Pharmacology & toxicology 1998;82(5):209-17.
1998: E Lukkari; Päivi Taavitsainen; A Juhakoski; Olavi Pelkonen
Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes.
Pharmacology & toxicology 1998;82(4):161-6.
1998: Janne Hukkanen; M Mäntylä; Lauri Kangas; P Wirta; Jukka Hakkola; P Paakki; S Evisalmi; Olavi Pelkonen; Hannu Raunio
Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium.
Pharmacology & toxicology 1998;82(2):93-7.
1998: Hannu Raunio; Risto O Juvonen; Markku Pasanen; Olavi Pelkonen; P Pääkkö; Y Soini
Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma.
Hepatology (Baltimore, Md.) 1998;27(2):427-32.
1998: Olavi Pelkonen; Hannu Raunio
[What do we know about the drug metabolism?].
Duodecim; lääketieteellinen aikakauskirja 1998;114(10):971-7.
1998: Jukka Hakkola; Olavi Pelkonen; Markku Pasanen; Hannu Raunio
Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity.
Critical reviews in toxicology 1998;28(1):35-72.
1998: Hannu Raunio; Jukka Hakkola; Janne Hukkanen; Olavi Pelkonen; R Edwards; Alan R Boobis; Sisko Anttila
Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues.
Archives of toxicology. Supplement. = Archiv für Toxikologie. Supplement 1998;20():465-9.
1997: Markku Pasanen; Z Rannala; A Tooming; Eero A Sotaniemi; Olavi Pelkonen; Arja Rautio
Hepatitis A impairs the function of human hepatic CYP2A6 in vivo.
Toxicology 1997;123(3):177-84.
1997: Janne Hukkanen; Jukka Hakkola; Sisko Anttila; Ritva Piipari; Antti Karjalainen; Olavi Pelkonen; Hannu Raunio
Detection of mRNA encoding xenobiotic-metabolizing cytochrome P450s in human bronchoalveolar macrophages and peripheral blood lymphocytes.
Molecular carcinogenesis 1997;20(2):224-30.
1997: H Kim; R S Wang; E Elovaara; H Raunio; Olavi Pelkonen; T Aoyama; H Vainio; T Nakajima
Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes.
Xenobiotica; the fate of foreign compounds in biological systems 1997;27(7):657-65.
1997: Olavi Pelkonen; H Raunio
Metabolic activation of toxins: tissue-specific expression and metabolism in target organs.
Environmental health perspectives 1997;105 Suppl 4():767-74.
1997: H Gullstén; José Agúndez; Julio Benitez; Esa Läärä; José M Ladero; M Díaz-Rubio; Pedro Fernandez-Salguero; F Gonzalez; Arja Rautio; Olavi Pelkonen; Hannu Raunio
CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis.
Pharmacogenetics 1997;7(3):247-50.
1997: Eero A Sotaniemi; A J Arranto; Olavi Pelkonen; Markku Pasanen
Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions.
Clinical pharmacology and therapeutics 1997;61(3):331-9.
1997: Sisko Anttila; Janne Hukkanen; Jukka Hakkola; Tuula Stjernvall; P Beaune; R J Edwards; Alan R Boobis; Olavi Pelkonen; Hannu Raunio
Expression and localization of CYP3A4 and CYP3A5 in human lung.
American journal of respiratory cell and molecular biology 1997;16(3):242-9.
1997: T Nakajima; R S Wang; E Elovaara; F J Gonzalez; H V Gelboin; H Raunio; Olavi Pelkonen; H Vainio; T Aoyama
Toluene metabolism by cDNA-expressed human hepatic cytochrome P450.
Biochemical pharmacology 1997;53(3):271-7.
1997: Tero I Ala-Kokko; Päivi K Pienimäki; ES Lampela; A I Hollmén; Olavi Pelkonen; Kirsi Vähäkangas
Transfer of clonidine and dexmedetomidine across the isolated perfused human placenta.
Acta anaesthesiologica Scandinavica 1997;41(2):313-9.
1997: Jukka Hakkola; Markku Pasanen; Olavi Pelkonen; Janne Hukkanen; S Evisalmi; Sisko Anttila; A Rane; M Mäntylä; R Purkunen; S Saarikoski; M Tooming; Hannu Raunio
Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells.
Carcinogenesis 1997;18(2):391-7.
1997: Markku Pasanen; HL Helin-Martikainen; Olavi Pelkonen; Pertti Kirkinen
Intrahepatic cholestasis of pregnancy impairs the activities of human placental xenobiotic and steroid metabolizing enzymes in vitro.
Placenta 1997;18(1):37-41.
1997: P Salonpää; S Kottari; Olavi Pelkonen; Hannu Raunio
Regulation of CYP 2 A 5 induction by porphyrinogenic agents in mouse primary hepatocytes.
Naunyn-Schmiedeberg's archives of pharmacology 1997;355(1):8-13.
1996: Jukka Hakkola; Hannu Raunio; R Purkunen; Olavi Pelkonen; S Saarikoski; Thierry CRESTEIL; Markku Pasanen
Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy.
Biochemical pharmacology 1996;52(2):379-83.
1996: A Kojo; P Pellinen; Risto O Juvonen; Hannu Raunio; Olavi Pelkonen; Markku Pasanen
Distinct responses of mouse hepatic CYP enzymes to corn oil and peroxisome proliferators.
Biochemical pharmacology 1996;51(9):1137-43.
1996: Jukka Hakkola; Markku Pasanen; Janne Hukkanen; Olavi Pelkonen; J Mäenpää; R J Edwards; Alan R Boobis; Hannu Raunio
Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta.
Biochemical pharmacology 1996;51(4):403-11.
1996: Olavi Pelkonen; V Saano; Hannu Jalanko
[Factors affecting prescription drugs].
Duodecim; lääketieteellinen aikakauskirja 1996;112(1):14-6.
1996: H Kraul; Markku Pasanen; Holger H Sigusch; Frej Stenbäck; S S Park; H V Gelboin; Olavi Pelkonen
Immunohistochemical properties of dipyrone-induced cytochromes P450 in rats.
Human & experimental toxicology 1996;15(1):45-50.
1996: AL Rauma; Arja Rautio; Markku Pasanen; Olavi Pelkonen; R Törrönen; Hannu M Mykkänen
Coumarin 7-hydroxylation in long-term adherents of a strict uncooked vegan diet.
European journal of clinical pharmacology 1996;50(1-2):133-7.
1995: Pedro Fernandez-Salguero; S M Hoffman; S Cholerton; Harvey W Mohrenweiser; H Raunio; Arja Rautio; Olavi Pelkonen; J D Huang; William Evans; Jeffrey Idle
A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles.
American journal of human genetics 1995;57(3):651-60.
1995: Tero I Ala-Kokko; Päivi K Pienimäki; R Herva; A I Hollmén; Olavi Pelkonen; Kirsi Vähäkangas
Transfer of lidocaine and bupivacaine across the isolated perfused human placenta.
Pharmacology & toxicology 1995;77(2):142-8.
1995: Jouko I T Isojärvi; K E Juhani Airaksinen; J N Mustonen; A J Pakarinen; Arja Rautio; Olavi Pelkonen; Vilho V Myllylä
Thyroid and myocardial function after replacement of carbamazepine by oxcarbazepine.
Epilepsia 1995;36(8):810-6.
1995: Hannu Raunio; K Husgafvel-Pursiainen; Sisko Anttila; E Hietanen; A Hirvonen; Olavi Pelkonen
Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review.
Gene 1995;159(1):113-21.
1995: P Salonpää; K Krause; Olavi Pelkonen; Hannu Raunio
Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver.
Naunyn-Schmiedeberg's archives of pharmacology 1995;351(4):446-52.
1995: Päivi K Pienimäki; Anna-Liisa Hartikainen; P Arvela; T Partanen; R Herva; Olavi Pelkonen; Kirsi Vähäkangas
Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood.
Epilepsia 1995;36(3):241-8.
1995: BB Rasmussen; J Maënpää; Olavi Pelkonen; S Loft; H E Poulsen; J Lykkesfeldt; Kim Brøsen
Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine.
British journal of clinical pharmacology 1995;39(2):151-9.
1995: E A Sotaniemi; Arja Rautio; M Bäckstrom; P Arvela; Olavi Pelkonen
CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.
British journal of clinical pharmacology 1995;39(1):71-6.
1995: Jouko I T Isojärvi; A J Pakarinen; Arja Rautio; Olavi Pelkonen; Vilho V Myllylä
Serum sex hormone levels after replacing carbamazepine with oxcarbazepine.
European journal of clinical pharmacology 1995;47(5):461-4.
1995: Markku Pasanen; P Pellinen; Frej Stenbäck; Risto O Juvonen; Hannu Raunio; Olavi Pelkonen
The role of CYP enzymes in cocaine-induced liver damage.
Archives of toxicology 1995;69(5):287-90.
1995: Olavi Pelkonen; Hannu Raunio
Individual expression of carcinogen-metabolizing enzymes: cytochrome P4502A.
Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine 1995;37(1):19-24.
1995: Imre Klebovich; Arja Rautio; P Salonpää; P Arvela; Olavi Pelkonen; E A Sotaniemi
Antipyrine, coumarin and glipizide affect n-acetylation measured by caffeine test.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1995;49(5):225-7.
1994: P Salonpää; Olavi Pelkonen; A Kojo; Markku Pasanen; M Negishi; Hannu Raunio
Cytochrome P4502A5 expression and inducibility by phenobarbital is modulated by cAMP in mouse primary hepatocytes.
Biochemical and biophysical research communications 1994;205(1):631-7.
1994: Jouko I T Isojärvi; A J Pakarinen; Arja Rautio; Olavi Pelkonen; Vilho V Myllylä
Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine.
Epilepsia 1994;35(6):1217-20.
1994: P Pellinen; Frej Stenbäck; Hannu Raunio; Olavi Pelkonen; Markku Pasanen
Modification of hepatic cytochrome P450 profile by cocaine-induced hepatotoxicity in DBA/2 mouse.
European journal of pharmacology 1994;292(1):57-65.
1994: T Nakajima; E Elovaara; F J Gonzalez; H V Gelboin; H Raunio; Olavi Pelkonen; H Vainio; Toshifumi Aoyama
Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450.
Chemical research in toxicology 1994;7(6):891-6.
1994: J Mäenpää; Risto O Juvonen; Hannu Raunio; Arja Rautio; Olavi Pelkonen
Metabolic interactions of methoxsalen and coumarin in humans and mice.
Biochemical pharmacology 1994;48(7):1363-9.
1994: Jukka Hakkola; Markku Pasanen; R Purkunen; S Saarikoski; Olavi Pelkonen; J Mäenpää; A Rane; Hannu Raunio
Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver.
Biochemical pharmacology 1994;48(1):59-64.
1994: Pertti Mustajoki; Sami Mustajoki; Arja Rautio; P Arvela; Olavi Pelkonen
Effects of heme arginate on cytochrome P450-mediated metabolism of drugs in patients with variegate porphyria and in healthy men.
Clinical pharmacology and therapeutics 1994;56(1):9-13.
1994: P Pellinen; Paavo Honkakoski; Frej Stenbäck; Matthias Niemitz; E Alhava; Olavi Pelkonen; M A Lang; Markku Pasanen
Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors.
European journal of pharmacology 1994;270(1):35-43.
1994: Olavi Pelkonen; Arja Rautio; Hannu Raunio; J Mäenpää; Jukka Hakkola
Regulation of coumarin 7-hydroxylation in man.
Journal of cancer research and clinical oncology 1994;120 Suppl():S30-1.
1994: Markku Pasanen; Olavi Pelkonen
The expression and environmental regulation of P450 enzymes in human placenta.
Critical reviews in toxicology 1994;24(3):211-29.
1994: Mümtaz Iscan; H Rostami; M Iscan; T Güray; Olavi Pelkonen; A Rautio
Interindividual variability of coumarin 7-hydroxylation in a Turkish population.
European journal of clinical pharmacology 1994;47(4):315-8.
1994: Olavi Pelkonen
[Cytochrome P-450 isoenzymes as predictors of drug interactions].
Duodecim; lääketieteellinen aikakauskirja 1994;110(17):1575-9.
1993: M Lähde; H Raunio; Olavi Pelkonen; Matti Karp; C Oker-Blom
Expression of human placental cytochrome P450 aromatase (CYP19) cDNA in insect cells using a luciferase based baculovirus vector.
Biochemical and biophysical research communications 1993;197(3):1511-7.
1993: N Bjelogrlic; R Peng; S S Park; H V Gelboin; Paavo Honkakoski; Olavi Pelkonen; Kirsi Vähäkangas
Involvement of P450 1A1 in benzo(a)pyrene but not in benzo(a)pyrene-7,8-dihydrodiol activation by 3-methylcholanthrene-induced mouse liver microsomes.
Pharmacology & toxicology 1993;73(6):319-24.
1993: Imre Klebovich; P Arvela; Olavi Pelkonen
HPLC method for rapid determination of acetylator phenotype by measuring urinary caffeine metabolites.
Journal of pharmaceutical and biomedical analysis 1993;11(10):1017-21.
1993: P Pellinen; Frej Stenbäck; Arja Rautio; Olavi Pelkonen; M Lang; Markku Pasanen
Response of mouse liver coumarin 7-hydroxylase activity to hepatotoxins: dependence on strain and agent and comparison to other monooxygenases.
Naunyn-Schmiedeberg's archives of pharmacology 1993;348(4):435-43.
1993: P Salonpää; Jukka Hakkola; Markku Pasanen; Olavi Pelkonen; Kirsi Vähäkangas; N Battula; Kazuhiro Nouso; Hannu Raunio
Retrovirus-mediated stable expression of human CYP2A6 in mammalian cells.
European journal of pharmacology 1993;248(2):95-102.
1993: J Mäenpää; Holger H Sigusch; Hannu Raunio; T Syngelmä; Pia Vuorela; Heikki Vuorela; Olavi Pelkonen
Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes.
Biochemical pharmacology 1993;45(5):1035-42.
1993: J Mäenpää; A Rane; Hannu Raunio; Paavo Honkakoski; Olavi Pelkonen
Cytochrome P450 isoforms in human fetal tissues related to phenobarbital-inducible forms in the mouse.
Biochemical pharmacology 1993;45(4):899-907.
1993: Ari Hirvonen; Kirsti Husgafvel-Pursiainen; Sisko Anttila; Antti Karjalainen; Olavi Pelkonen; Harri Vainio
PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Pharmacogenetics 1993;3(1):19-27.
1993: Paavo Honkakoski; J Mäenpää; J Leikola; Markku Pasanen; Risto O Juvonen; M A Lang; Olavi Pelkonen; Hannu Raunio
Cytochrome P4502A-mediated coumarin 7-hydroxylation and testosterone hydroxylation in mouse and rat lung.
Pharmacology & toxicology 1993;72(2):107-12.
1993: J Mäenpää; Olavi Pelkonen; Thierry CRESTEIL; Anders Rane
The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver.
The Journal of steroid biochemistry and molecular biology 1993;44(1):61-7.
1992: Jukka Hakkola; J Mäenpää; R T Mayer; S S Park; H V Gelboin; Olavi Pelkonen
7-Alkoxyquinoline O-dealkylation by microsomes from human liver and placenta.
British journal of clinical pharmacology 1992;34(5):415-20.
1992: P Salonpää; M Iscan; Markku Pasanen; P Arvela; Olavi Pelkonen; Hannu Raunio
Cerium-induced strain-dependent increase in Cyp2a-4/5 (cytochrome P4502a-4/5) expression in the liver and kidneys of inbred mice.
Biochemical pharmacology 1992;44(7):1269-74.
1992: Arja Rautio; H Kraul; A Kojo; E Salmela; Olavi Pelkonen
Interindividual variability of coumarin 7-hydroxylation in healthy volunteers.
Pharmacogenetics 1992;2(5):227-33.
1992: B Hahnemann; P Salonpää; Markku Pasanen; J Mäenpää; Paavo Honkakoski; Risto O Juvonen; M A Lang; Olavi Pelkonen; Hannu Raunio
Effect of pyrazole, cobalt and phenobarbital on mouse liver cytochrome P-450 2a-4/5 (Cyp2a-4/5) expression.
The Biochemical journal 1992;286 ( Pt 1)():289-94.
1992: U Tacke; E Leinonen; Pirjo Lillsunde; T Seppälä; P Arvela; Olavi Pelkonen; P Ylitalo
Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations.
Journal of clinical psychopharmacology 1992;12(4):262-7.
1992: Paavo Honkakoski; P Arvela; Risto O Juvonen; M A Lang; M Kairaluoma; Olavi Pelkonen
Human and mouse liver coumarin 7-hydroxylases do not metabolize warfarin in vitro.
British journal of clinical pharmacology 1992;33(3):313-7.
1992: Olavi Pelkonen
Carcinogen metabolism and individual susceptibility.
Scandinavian journal of work, environment & health 1992;18 Suppl 1():17-21.
1991: Olavi Pelkonen; J Puurunen; P Arvela; R Lammintausta
Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism.
Pharmacology & toxicology 1991;69(3):189-94.
1991: J Mäenpää; T Syngelmä; Paavo Honkakoski; M A Lang; Olavi Pelkonen
Comparative studies on coumarin and testosterone metabolism in mouse and human livers. Differential inhibitions by the anti-P450Coh antibody and metyrapone.
Biochemical pharmacology 1991;42(6):1229-35.
1991: Z Kocer; Hannu Raunio; Markku Pasanen; P Arvela; T Raiskila; Paavo Honkakoski; M A Lang; M Negishi; Olavi Pelkonen
Comparison between cobalt and pyrazole in the increased expression of coumarin 7-hydroxylase in mouse liver.
Biochemical pharmacology 1991;41(3):462-5.
1991: P Arvela; H Kraul; Frej Stenbäck; Olavi Pelkonen
The cerium-induced liver injury and oxidative drug metabolism in DBA/2 and C57BL/6 mice.
Toxicology 1991;69(1):1-9.
1991: P Arvela; Olavi Pelkonen; L Pyy; E Sotaniemi; Kirsi Vähäkangas; E Yrjänheikki
Antipyrine metabolism in coke oven workers.
Archives of toxicology. Supplement. = Archiv für Toxikologie. Supplement 1991;14():201-4.
1991: H Kraul; Markku Pasanen; Olavi Pelkonen
The effect of monoclonal antibodies on dipyrone-induced rat liver cytochrome P450.
Archives of toxicology. Supplement. = Archiv für Toxikologie. Supplement 1991;14():197-200.
1991: M Luotamo; E Elovaara; Hannu Raunio; Olavi Pelkonen; Vesa Riihimäki; Harri Vainio
Distribution and effects on cytochrome P450 system of two hexachlorobiphenyl isomers in the rat.
Archives of toxicology 1991;65(8):661-5.
1990: Hannu Raunio; J Valtonen; Paavo Honkakoski; M A Lang; M Ståhlberg; M A Kairaluoma; Arja Rautio; Markku Pasanen; Olavi Pelkonen
Immunochemical detection of human liver cytochrome P450 forms related to phenobarbital-inducible forms in the mouse.
Biochemical pharmacology 1990;40(11):2503-9.
1990: Alan R Boobis; D Sesardic; B P Murray; Robert J Edwards; A M Singleton; K J Rich; Stephen Murray; Rafael de la Torre; Jordi Segura; Olavi Pelkonen
Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors.
Xenobiotica; the fate of foreign compounds in biological systems 1990;20(11):1139-61.
1990: D Sesardic; M Pasanen; Olavi Pelkonen; Alan R Boobis
Differential expression and regulation of members of the cytochrome P450IA gene subfamily in human tissues.
Carcinogenesis 1990;11(7):1183-8.
1990: Markku Pasanen; T Haaparanta; M Sundin; P Sivonen; K Vakakangas; Hannu Raunio; Ronald Hines; J A Gustafsson; Olavi Pelkonen
Immunochemical and molecular biological studies on human placental cigarette smoke-inducible cytochrome P-450-dependent monooxygenase activities.
Toxicology 1990;62(2):175-87.
1990: Hannu Raunio; J Liira; E Elovaara; Vesa Riihimäki; Olavi Pelkonen
Cytochrome P450 isozyme induction by methyl ethyl ketone and m-xylene in rat liver.
Toxicology and applied pharmacology 1990;103(1):175-9.
1990: Markku Pasanen; Olavi Pelkonen
Xenobiotic and steroid-metabolizing monooxygenases catalysed by cytochrome P450 and glutathione S-transferase conjugations in the human placenta and their relationships to maternal cigarette smoking.
Placenta 1990;11(1):75-85.
1990: D Brauze; R Mikstacka; Olavi Pelkonen
Monoclonal antibody characterization of NADH- and NADPH-dependent hydroxylation of benzo(a)pyrene in liver microsomes from 5,6-benzoflavone-induced C57Bl/6 mice.
Acta biochimica Polonica 1990;37(2):219-25.
1990: Olavi Pelkonen; M Lang; E Sotaniemi
[Cytochrome P-450 enzymes].
Duodecim; lääketieteellinen aikakauskirja 1990;106(7):555-62.
1989: Sergey A Usanov; Paavo Honkakoski; M A Lang; M Pasanen; Olavi Pelkonen; H Raunio
Comparison of the immunochemical properties of human placental and bovine adrenal cholesterol side-chain cleavage enzyme complex.
Biochimica et biophysica acta 1989;998(2):189-95.
1989: A Kojo; Paavo Honkakoski; P Järvinen; Olavi Pelkonen; M Lang
Preferential inhibition of mouse hepatic coumarin 7-hydroxylase by inhibitors of steroid metabolizing monooxygenases.
Pharmacology & toxicology 1989;65(2):104-9.
1989: J Mäenpää; H Ruskoaho; Olavi Pelkonen
Inhibition of hepatic microsomal drug metabolism in rats by five calcium antagonists.
Pharmacology & toxicology 1989;64(5):446-50.
1989: N Bjelogrlic; M Iscan; Hannu Raunio; Olavi Pelkonen; Kirsi Vähäkangas
Benzo[a]pyrene-DNA-adducts and monooxygenase activities in mice treated with benzo[a]pyrene, cigarette smoke or cigarette smoke condensate.
Chemico-biological interactions 1989;70(1-2):51-61.
1989: Markku Pasanen; Olavi Pelkonen
Human placental xenobiotic and steroid biotransformations catalyzed by cytochrome P450, epoxide hydrolase, and glutathione S-transferase activities and their relationships to maternal cigarette smoking.
Drug metabolism reviews 1989;21(3):427-61.
1989: Kirsi Vähäkangas; Hannu Raunio; Markku Pasanen; P Sivonen; S S Park; H V Gelboin; Olavi Pelkonen
Comparison of the formation of benzo[a]pyrene diolepoxide-DNA adducts in vitro by rat and human microsomes: evidence for the involvement of P-450IA1 and P-450IA2.
Journal of biochemical toxicology 1989;4(2):79-86.
1988: Paavo Honkakoski; S Autio; Risto O Juvonen; Hannu Raunio; H V Gelboin; S S Park; Olavi Pelkonen; M A Lang
Pyrazole is different from acetone and ethanol as an inducer of the polysubstrate monooxygenase system in mice: evidence that pyrazole-inducible P450Coh is distinct from acetone-inducible P450ac.
Archives of biochemistry and biophysics 1988;267(2):589-98.
1988: P Arvela; M Kirjarinta; M Kirjarinta; N Kärki; Olavi Pelkonen
Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
British journal of clinical pharmacology 1988;26(5):601-3.
1988: Hannu Raunio; A Kojo; Risto O Juvonen; Paavo Honkakoski; P Järvinen; M A Lang; Kirsi Vähäkangas; H V Gelboin; S S Park; Olavi Pelkonen
Mouse hepatic cytochrome P-450 isozyme induction by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene, pyrazole, and phenobarbital.
Biochemical pharmacology 1988;37(21):4141-7.
1988: Markku Pasanen; T Taskinen; M Iscan; E A Sotaniemi; M Kairaluoma; Olavi Pelkonen
Inhibition of human hepatic and placental xenobiotic monooxygenases by imidazole antimycotics.
Biochemical pharmacology 1988;37(20):3861-6.
1988: Hannu Raunio; T Syngelmä; Markku Pasanen; Risto O Juvonen; Paavo Honkakoski; M A Kairaluoma; E Sotaniemi; M A Lang; Olavi Pelkonen
Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse.
Biochemical pharmacology 1988;37(20):3889-95.
1988: Markku Pasanen; T Taskinen; E A Sotaniemi; M Kairaluoma; Olavi Pelkonen
Inhibitor panel studies of human hepatic and placental cytochrome P-450-associated monooxygenase activities.
Pharmacology & toxicology 1988;62(5):311-7.
1988: Markku Pasanen; F Stenbäck; S S Park; H V Gelboin; Olavi Pelkonen
Immunohistochemical detection of human placental cytochrome P-450-associated mono-oxygenase system inducible by maternal cigarette smoking.
Placenta 1988;9(3):267-75.
1988: Markku Pasanen; K Vahakangas; E A Sotaniemi; Olavi Pelkonen
The effect of cigarette smoking on drug metabolism in the liver and placenta: the use of cotinine in verifying smoking status.
European journal of drug metabolism and pharmacokinetics 1988;13(1):41-5.
1988: Kirsi Vähäkangas; Olavi Pelkonen; C C Harris
Synchronous fluorescence spectrophotometry of benzo[a]pyrene diol epoxide-DNA adducts: a tool for detection of in-vitro and in-vivo DNA damage by exposure to benzo[a]pyrene.
IARC scientific publications 1988;(89):208-12.
1987: R Pahlman; Olavi Pelkonen
Mutagenicity studies of different polycyclic aromatic hydrocarbons: the significance of enzymatic factors and molecular structure.
Carcinogenesis 1987;8(6):773-8.
1987: N T Kärki; R Pokela; L Nuutinen; Olavi Pelkonen
Aryl hydrocarbon hydroxylase in lymphocytes and lung tissue from lung cancer patients and controls.
International journal of cancer. Journal international du cancer 1987;39(5):565-70.
1987: Olavi Pelkonen; E A Sotaniemi
Environmental factors of enzyme induction and inhibition.
Pharmacology & therapeutics 1987;33(1):115-20.
1987: U Klotz; P Arvela; M Pasanen; H Kroemer; Olavi Pelkonen
Comparative effects of H2-receptor antagonists on drug metabolism in vitro and in vivo.
Pharmacology & therapeutics 1987;33(1):157-62.
1986: Markku Pasanen; P Arvela; Olavi Pelkonen; E Sotaniemi; U Klotz
Effect of five structurally diverse H2-receptor antagonists on drug metabolism.
Biochemical pharmacology 1986;35(24):4457-61.
1986: Olavi Pelkonen; M Pasanen; H Kuha; B Gachalyi; M Kairaluoma; E A Sotaniemi; S S Park; Fred Friedman; H V Gelboin
The effect of cigarette smoking on 7-ethoxyresorufin O-deethylase and other monooxygenase activities in human liver: analyses with monoclonal antibodies.
British journal of clinical pharmacology 1986;22(2):125-34.
1986: M Pasanen; Olavi Pelkonen
Purification and immunological characterization of human placental mitochondrial cytochrome P-450.
Journal of steroid biochemistry 1986;24(3):669-75.